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INTRODUCTION
Susceptibility to autoimmune disease is
multifactorial and includes genetic predis-
position, gender, ethnicity, age, and envi-
ronment. While no single factor has been
identified as preeminent, the role of the
environment has garnered increasing inter-
est. This reflects the ubiquitous nature
of the environment, which encompasses
everything around us including the air we
breathe, the water we drink, the food we eat,
synthetic and natural chemicals, microor-
ganisms, industrial by-products, and phys-
ical factors such as radiation (1). The most
convincing evidence for a role of exogenous
factors in autoimmunity comes from stud-
ies implicating numerous medications in
the induction of autoimmune disease, par-
ticularly the association of drug-induced
systemic lupus erythematosus (SLE) with
procainamide and hydralazine (2). Identi-
fication of the causal role of medications
in the induction of autoimmune disease
is due in large part to the fact that med-
ications are taken under medical supervi-
sion where drug exposure and possible side
effects can be closely monitored. This is not
the case with non-therapeutic exposure to
environmental factors where contact may
include numerous exogenous factors at
any particular time. Nonetheless, evidence
for the association of (non-therapeutic)
environmental exposure with autoimmu-
nity has come from two well documented
exposures. In 1981, in Spain, the inges-
tion of analine adulterated rapeseed oil
was linked to a previously unknown dis-
ease, subsequently called toxic oil syn-
drome (TOS), which was characterized by
myalgias, peripheral eosinophilia, and pul-
monary infiltrates (3). The adulterated oil
was sold as “olive oil” by street vendors and
subsequently used for cooking. The deter-
mination that the adulterated oil was the
cause of TOS was based on robust epi-
demiological evidence. More than 20,000
people were affected and some 2,000 per-
ished. Chronic conditions, including scle-
roderma and neurologic changes, have
been described in the survivors. A clini-
cally similar, though epidemiologically dis-
tinct, syndrome was identified in United
States in 1989 (3, 4). Eosinophilia myalgia
syndrome (EMS) affecting approximately
1,500 individuals was suggested to be due
to ingestion of certain lots of l-tryptophan
from a single manufacturer. Akin to TOS,
EMS is a scleroderma-like syndrome found
more frequently in women but unlike TOS
was not restricted to a geographical area.
The acute phase of the syndrome was
characterized by myalgia and eosinophilia,
followed by chronic cutaneous lesions, pro-
gressive neuropathy, and myopathy. These
causative exposures are rare examples in a
field hampered by the difficulty of linking
putative environmental risk factors with
autoimmune disease in humans.
Recently, the National Institute of Envi-
ronmental Health Sciences (NIEHS) con-
vened an expert panel in a workshop setting
to review the role of the environment in the
development of autoimmune disease. The
meeting addressed specific areas of mecha-
nisms, animal models, epidemiology, diag-
nostic criteria, and exposure assessment
focusing, in particular, on the contribution
of chemical, physical, and biological agent
exposures; medications were not consid-
ered. A series of papers were published
summarizing the workshop findings (5–
8), and a consensus statement was recently
published (9). Together these publications
constitute the most recent summary of the
state of knowledge on the role of environ-
mental exposures in autoimmune disease.
In this opinion piece, I will expand upon
some of the findings of the NIEHS work-
shop and our own studies to examine how
environmental exposure can contribute to
our understanding of autoimmunity and
autoimmune diseases.
ASSOCIATION BETWEEN HUMAN
AUTOIMMUNE DISEASES AND
ENVIRONMENTAL EXPOSURES
A significant outcome of the NIEHS work-
shop was analysis of peer reviewed epi-
demiology studies of environmental expo-
sures that are associated with autoimmu-
nity in humans from 1980 to 2010 (6).
This investigation focused on three broad
classes of environmental exposures; chem-
ical, physical, and biological but excluded
studies of therapeutic agents, vaccines,
and medical devices. Previously estab-
lished guidelines for environmental expo-
sures and human disease were used to
classify exposures as “confident,” “likely,”
and “unlikely” to contribute to devel-
opment of disease based on exposure-
disease associations, numbers of studies,
established exposure assessment, exposure-
response gradient, and evidence of biolog-
ical plausibility. The most striking of the
consensus findings was confidence in the
association of silica exposure with several
autoimmune diseases including SLE and
scleroderma (Table 1). Additional findings
included confidence in the linkage between
solvents and scleroderma, and smoking
and seropositive RA (Table 1). Smoking
was considered “likely” to contribute to
seronegative RA, SLE, multiple sclerosis,
Hashimoto’s thyroiditis, Graves’ disease,
and Crohn’s disease, but to be protective
www.frontiersin.org February 2015 | Volume 6 | Article 60 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pollard Environment and autoimmunity
Table 1 | Environmental exposures for which there is confidence of an association with human autoimmune diseasea.
Category Agent Disease Exposure Gender
Chemical Silica RA Occupational Increased risk for males
SLE Occupational Both sexes affected
Scleroderma (systemic sclerosis) Occupational Increased risk for males
ANCA-associated vasculitis Occupational Increased risk for males
Solvents Scleroderma (systemic sclerosis) Occupational Increased risk for males
Smoking Seropositive RA Smoking history Increased risk for both sexes
Physical Sunlight Multiple sclerosis (exposure protective) Various Global none; Canada female, New Zealand female
Biological Gluten Gluten-sensitive enteropathy (celiac disease) Diet Increased risk for females
aAdapted from Ref. (1, 6).
against ulcerative colitis. While the NIEHS
workshop analysis identified numerous
epidemiological studies supporting the
contribution of environmental exposure
to autoimmune diseases, it also concluded
that considerably more research is needed.
Greater understanding is required of the
types of environmental exposures that lead
to autoimmunity, importance of latency
period between exposure and presentation
of autoimmunity, dose–response relation-
ships, and effects of age, sex, and devel-
opmental stage. Significant gaps also exist
in our understanding of how genotype
(how an individual differs or is specialized
within a group of individuals or a species)
influences induction of autoimmunity fol-
lowing environmental exposure and how
broad is the spectrum of disease pheno-
types that develop. Also, important will be
greater understanding of how epigenetic
mechanisms, including DNA methylation,
histone modifications, micro- and long
non-coding RNAs, influence gene and dis-
ease expression following environmental
exposure.
Another limitation in our understand-
ing of environmental-induced autoim-
mune diseases is the development of
criteria that can be used to diagnose
and treat autoimmune disease phenotypes
resulting from environmental exposure
(7). This is likely to be a particu-
larly difficult task and will require con-
sideration of many lines of evidence
including clinical, serologic, genetic, epige-
netic, and other features. Fortunately, our
current understanding of environment-
exposure associations provides some help.
For example, many autoimmune diseases
show a female predominance particularly
SLE, scleroderma, and rheumatoid arthri-
tis (RA) where up to 90% of patients may
be female (10). However, this is often not
observed when studies consider environ-
mental exposures (1). This often reflects
the occupational or other gender biased
social and cultural activities associated with
exposure (Table 1). Thus, silica exposure is
associated with greater risk of autoimmune
disease in males due to occupational bias of
males in dusty trades such as mining (11).
Such distinctions allow us to identify rel-
evant cohorts to study in order to more
accurately define appropriate diagnostic
criteria.
ENVIRONMENTAL EXPOSURE AND
MECHANISMS OF AUTOIMMUNITY
Little is known about the mechanisms that
lead to autoimmunity following environ-
mental exposure (8, 12). This is due in
large part to a lack of accepted criteria
for diagnosis and/or classification of envi-
ronmentally associated autoimmunity (7).
Mechanistic studies are also hampered by
the paucity of animal models that faith-
fully mimic human exposure, an excel-
lent example being the failure to repro-
duce TOS in mice. Furthermore, although
animal models have provided insight to
our understanding of disease mechanisms
(e.g., the pristane-induced lupus model),
they often recapitulate only some of the
facets of human disease (5). In contrast,
a wide range of environmental agents
have been shown to aggravate disease
in autoimmune-prone mice, arguing that
genetic susceptibility can be influenced
by environmental exposure (5). Such dis-
ease exacerbation in a genetically sus-
ceptible host supports the importance of
gene–environment interactions in autoim-
munity.
Limited data from human studies sug-
gest that environmental agents elicit both
common and unique features of autoim-
munity, and this is supported by animal
studies (9). For example, the association of
silica exposure with SLE is supported by the
presence of disease relevant autoantibodies
in humans and mice as well as alterations
in T cells subsets. Similarly, the effects
of the solvent trichloroethylene (TCE)
on cytokine profiles observed in humans
have been recapitulated in animal stud-
ies. Moreover, both silica and TCE exac-
erbate systemic autoimmunity in lupus-
prone strains. In the case of seropositive
RA and smoking, the observed increase of
heat shock protein expression and disease
associated autoantibodies, such as rheuma-
toid factor (RF) and anti-HSP70, have
been observed in animal studies. The com-
mon outcome of autoantibody production
clearly suggests that environmental fac-
tors influence adaptive immune responses.
However, the resulting autoantibody pro-
files suggest that different exposures lead
to responses against different autoantigens.
Such exposure-specific responses may be
useful diagnostic markers and may provide
some insight into disease mechanisms (13).
ENVIRONMENTAL EXPOSURES CAN
LEAD TO AUTOIMMUNITY BUT NOT
AUTOIMMUNE DISEASE
For some exposures evidence of immune
activation and/or autoantibodies is not
linked to any specific autoimmune dis-
ease (6). Asbestos (a silicate) exposure is
associated with elevated immunoglobulins,
anti-nuclear antibodies (ANA), and RF, but
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not strong evidence of specific autoim-
mune disease. Anti-thyroid antibodies have
been found following radiation exposure,
from the nuclear accident at the Cher-
nobyl Nuclear Power Plant in Ukraine,
during infancy or early childhood with-
out evidence of thyroiditis. Mercury expo-
sure from artisanal gold mining is associ-
ated with features of immune activation
and autoimmunity including proinflam-
matory cytokines and ANA, but the pres-
ence of autoimmune disease has not been
established.
Although there is little epidemiological
evidence that mercury exposure is asso-
ciated with specific autoimmune diseases
(6, 14), it does produce non-life threat-
ening autoimmunity in mice (5) that is
regulated by several genes known to be
important in idiopathic systemic autoim-
mune disease (12). What limits the sever-
ity of mercury-induced autoimmunity in
humans and animal models is unknown,
but a recent study suggests that mercury
exposure by itself may not be sufficient for
expression of autoimmunity in humans.
Mercury is a ubiquitous toxicant in the
Cheyenne River Sioux Tribe (CRST) lands
in United States due to mercury in water-
sheds of CRST as a result of gold min-
ing in the Black Hills of South Dakota.
The predominant mercury (Hg) exposure
in the CRST population is thought to be
via fish consumption. The association of
ANA and specific autoantibodies in rela-
tion to total blood Hg, and Hg expo-
sure through fish eating and smoking has
been examined in a cohort of 75 regu-
lar fish consumers (15). Gender, age, and
fish eating were significant predictors of
total Hg and specific autoantibodies; self-
reported smoking was not. Although ANA
was not significantly associated with Hg
alone, the interactions of gender with Hg
and proximity to arsenic deposits were
statistically significant. Of the 75 par-
ticipants, 38 were male and 37 female
with 5% of males and 24% of females
being ANA positive. Among the specific
autoantibodies tested, the most notewor-
thy were those against Sjögren’s-syndrome-
related antigen A components 60 and
52 kDa, Sjögren’s-syndrome-related anti-
gen A 52 kDa alone, centromere proteins
A and B (CENP-A/B), immunodominant
epitopes of the E2 subunits of the pyruvate
dehydrogenase complex (PDC-E2), the
branched-chain 2-oxo-acid dehydrogenase
complex (BCOADC-E2), and the 2-oxo
glutarate dehydrogenase complex (OGDC-
E2) (M2 EP/MIT3), and the autoanti-
bodies detected in a primary biliary cir-
rhosis (PBC) panel consisting of MIT3,
and synthetic peptides of nuclear pore
glycoprotein-210 (gp210) and nuclear anti-
gen Sp100 (sp100). The most common
being autoantibodies to M2 EP (MIT3)
(15%) and the PBC panel (24%), which
may echo the high rates of idiopathic liver
cirrhosis in Sioux communities; whether
this reflects an environmental and/or eth-
nic etiology is unknown. To date (Febru-
ary 2015), no autoimmune diseases have
been associated with this cohort. The con-
tribution that additional factors, such as
gender and ethnicity, play in develop-
ment of autoimmunity induced by envi-
ronmental exposure requires more detailed
elaboration.
CONCLUSION
Strong evidence that environmental expo-
sure can cause autoimmune disease comes
from epidemiologic studies showing the
association between a diversity of envi-
ronmental exposures and an assortment
of autoimmune diseases. This is further
supported by the observation that gen-
der ratios may differ from that of idio-
pathic autoimmune disease due to the
occupational nature of exposure. Progress,
however, in identifying and characterizing
the presumably large number of environ-
mental factors is hampered by the lack
of accepted criteria for diagnosis and/or
classification of environmentally associ-
ated autoimmunity. Postulated mecha-
nisms suggest that specific types of expo-
sures lead to specific outcomes in both
humans and animal models. Environmen-
tal exposures can also commonly result
in immune activation and autoimmunity
without evidence of a defined autoim-
mune disease. The best example is expo-
sure to mercury, which in humans and
animal models, produces autoimmunity
and tissue pathology that is mild in sever-
ity. Greater understanding of how dif-
ferent environmental exposures result in
different disease phenotypes and varying
degrees of severity will help identify the
mechanisms and checkpoints that con-
trol development of autoimmunity and
autoimmune disease.
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